Gilead Sciences, Inc. (NASDAQ: GILD) – Analyst View Is Different Today

In the last trading session, 5.23 million shares of the Gilead Sciences, Inc. (NASDAQ:GILD) were traded, and its beta was 0.23. Most recently the company’s share price was $67.03, and it changed around $0.08 or 0.12% from the last close, which brings the market valuation of the company to $83.58B. GILD currently trades at a discount to its 52-week high of $87.86, offering almost -31.08% off that amount. The share price’s 52-week low was $65.90, which indicates that the current value has risen by an impressive 1.69% since then. We note from Gilead Sciences, Inc.’s average daily trading volume that its 3-month average coming to 7.24 million.

Gilead Sciences, Inc. stock received a consensus recommendation rating of Hold, based on a mean score of 2.28. If we narrow it down even further, the data shows that 0 out of 28 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 15 recommended GILD as a Hold, whereas 11 deemed it a Buy, and 0 rated it as Underweight. Gilead Sciences, Inc. is expected to report earnings per share of -$1.42 for the current quarter.

Gilead Sciences, Inc. (NASDAQ:GILD) trade information

Instantly GILD has showed a green trend with a performance of 0.12% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -17.26% year-to-date, but still down -0.42% over the last five days. On the other hand, Gilead Sciences, Inc. (NASDAQ:GILD) is -7.68% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $79.25, which translates to bulls needing to increase their stock price by 15.42% from its current value. Analyst projections state that GILD is forecast to be at a low of $54 and a high of $112.

Gilead Sciences, Inc. (GILD) estimates and forecasts

Gilead Sciences, Inc. share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -13.84 percent over the past six months and at a -6.55% annual growth rate that is well below the industry average of 13.00%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -203.60% in revenue this quarter, and will report an increase of 18.70% in the next quarter. The year-over-year growth rate is expected to be 1.40%, up from the previous year.

Consensus estimates provided by 22 financial analysts predict the company will bring in an average of $5.95 billion in revenue for the current quarter. 20 analysts expect Gilead Sciences, Inc. to make $6.36 billion in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $6.35 billion and $6.6 billion respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -6.40%. Forecasts for the next quarter put sales growth at -3.70%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.55%. Gilead Sciences, Inc. earnings are expected to increase by -42.37% in 2024, but the outlook is positive 5.38% per year for the next five years.

GILD Dividends

Gilead Sciences, Inc.’s next quarterly earnings report is expected to be released in May. The annual dividend yield of the stock is 4.51 percent and its annual dividend per share was 3.02. It is important to note, however, that the 4.51% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision.